Ch. I — Historical arc and sociocultural reframing

Chapter I of Post-2010 Psychedelics: An Expert-Panel Review. For the executive summary and full table of contents, start there.

Abstract. This chapter traces the historical scaffolding on which the post-2010 psychedelic field has been built — from Albert Hofmann’s 1943 LSD synthesis through the Schedule I lockdown of 1970, the long quiet period sustained by a small number of mission-driven non-profits, the imaging-and-mystical-experience renaissance of the 1990s and 2000s, the venture-fuelled mainstreaming of the 2010s, and the regulatory and reputational correction of 2024. It frames the present moment (2026) as a chastened, bifurcated field in which industrial clinical development and grassroots state-level reform are advancing on visibly different timelines and under visibly different epistemic norms. Methodology critique of specific trials and Indigenous-use history are treated separately (Chapters XII and X respectively).

1.1 Pre-renaissance: chemistry, ceremony, and the first clinical wave

The modern Western pharmacology of psychedelics begins, by accident, on 16 April 1943, when Albert Hofmann re-examined lysergic acid diethylamide (LSD-25), a compound he had first synthesised at Sandoz in Basel on 16 November 1938 as part of a programme aimed at ergot-derived circulatory stimulants.¹ Three days after the inadvertent dermal exposure of 16 April, Hofmann self-administered 250 µg — a dose he believed conservative but which is now understood to be roughly five times a recreational threshold — and made his way home by bicycle, an episode commemorated annually as Bicycle Day. Sandoz subsequently distributed LSD to qualified psychiatric researchers under the trade name Delysid from 1947, accompanied by a circular suggesting two indications: as an adjunct to analytical psychotherapy and, controversially, as a “psychotomimetic” tool to induce a transient model psychosis for research purposes.²

A second strand entered the Western record a decade later. The amateur mycologist R. Gordon Wasson described his 1955 participation in a velada led by the Mazatec curandera María Sabina in Huautla de Jiménez (Sierra Mazateca, Oaxaca, Mexico) in the 17 May 1957 issue of Life magazine (“Seeking the Magic Mushroom”), an article that placed Psilocybe mushrooms before a general readership of roughly five million.³ Hofmann isolated and synthesised psilocybin and psilocin from Wasson’s specimens at Sandoz the following year. The episode is the canonical case study of extractive psychedelic ethnography: Wasson had been granted access on a promise of secrecy that he then broke, and the disclosure produced a multi-decade fallout for Sabina and the Huautla community (tourism, federal raids, the burning of Sabina’s home, community censure, Sabina’s own later report that the mushrooms had “lost their power”). It is also the historical root of the contemporary structural-reciprocity question that runs through Chapter X §10.6–10.7 and Chapter XIII §13.6: the multi-billion-dollar psilocybin commercial-development ecosystem traced through the rest of this chapter rests, demonstrably, on a transmission of knowledge whose source community has, to public knowledge, received no equivalent structural reciprocity from any commercial-stage developer to date.

The nomenclature of the field carries the marks of these two origins. Humphry Osmond, working with the Saskatchewan group around Abram Hoffer, coined “psychedelic” — from the Greek psyche and delos, “mind-manifesting” — in a 1957 letter to Aldous Huxley, deliberately as an alternative to the clinically loaded “psychotomimetic” and “hallucinogen.”⁴ The choice mattered: it signalled a programmatic break from the model-psychosis framing and toward a positively valenced, experiential one. By the early 1960s an unusually productive North American research scene was operating in parallel: the Spring Grove studies of LSD-assisted psychotherapy for alcoholism, neurosis and end-of-life distress at the Maryland Psychiatric Research Center under Albert Kurland, Stanislav Grof, Walter Pahnke and others; the Harvard Psilocybin Project under Timothy Leary and Richard Alpert (1960–1963), terminated after departures from research norms and the involvement of undergraduates; and the human-potential matrix at Esalen Institute in Big Sur, where psychiatrists, philosophers and clinicians cross-pollinated with the counterculture. By 1965, more than a thousand papers describing roughly forty thousand patients had been published on LSD alone.⁵

1.2 The hiatus: 1970–c.2000

The collapse was simultaneously political and infrastructural. The U.S. Controlled Substances Act of 1970 placed LSD, psilocybin, mescaline and (from 1985) MDMA in Schedule I, the most restrictive category, on findings of high abuse potential and no accepted medical use; the 1971 United Nations Convention on Psychotropic Substances generalised analogous controls internationally. Schedule I status did not, as is sometimes asserted, prohibit research outright, but it imposed DEA registration, security and storage requirements, and a procurement bottleneck (a single NIDA-licensed manufacturer in the U.S.) that — combined with the loss of NIH funding interest after the Leary-era reputational damage — made academic work practically untenable for roughly a generation.⁶

What survived did so largely outside the universities. The Multidisciplinary Association for Psychedelic Studies (MAPS) was founded in 1986 by Rick Doblin specifically to pursue MDMA-assisted psychotherapy through the FDA pathway following MDMA’s emergency Schedule I placement;⁷ Doblin describes operating as the sole staff member from 1986 to 1993.⁷ The Heffter Research Institute, incorporated in New Mexico in 1993 by the medicinal chemist David E. Nichols, was modelled as a non-profit funder of psilocybin research — initially with a focus on end-of-life anxiety and substance-use disorders.⁸ The Beckley Foundation, founded by Amanda Feilding in the United Kingdom in 1998, played a parallel philanthropic and political role. None of these organisations was large; collectively they preserved the field’s continuity through the lean decades.

1.3 Renaissance triggers, c.1995–2010

Three threads re-opened academic respectability. First, Rick Strassman conducted DMT pharmacology studies at the University of New Mexico from 1990 to 1995, administering approximately 400 doses to about 60 volunteers under DEA Schedule I authorisation — the first government-approved psychedelic research on humans in the U.S. in roughly two decades.⁹ His 2001 trade book DMT: The Spirit Molecule is best understood as a cultural artefact rather than a scientific source, but the underlying programme broke a procedural ice.

Second, Franz Vollenweider’s group at the University of Zurich Psychiatric Hospital initiated a sustained imaging and pharmacology programme on psilocybin and ketanserin-blockade beginning in the late 1990s, including the Neuroreport demonstration that 5-HT2A receptor antagonism by ketanserin abolished the psilocybin experience — the empirical foundation of the receptor pharmacology developed in Chapter III.¹⁰

Third — and the most consequential inflection for public and clinical perception — Roland Griffiths and colleagues at Johns Hopkins published “Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance” in Psychopharmacology (often catalogued under J. Psychopharmacol. indices) in 2006.¹¹ In thirty-six hallucinogen-naïve volunteers receiving 30 mg/70 kg psilocybin under a double-blind comparison with 40 mg/70 kg methylphenidate, the psilocybin condition produced acute experiences that participants rated, two months later, among the five most personally meaningful events of their lives. The paper’s design — a careful set-and-setting protocol, validated mystical-experience instrumentation (the MEQ), and a published consent and safety framework — became the methodological template for the trials of the following decade and is widely treated as the modal inflection point of the renaissance.

1.4 Mainstreaming, c.2010–2023

If 2006 re-established academic legitimacy, the 2010s established institutional and commercial reach. The Beckley/Imperial Psychedelic Research Programme, formalised at Imperial College London when David Nutt arrived in 2008 and Robin Carhart-Harris joined as lead investigator in 2009, generated the first modern open-label psilocybin trial for treatment-resistant depression (Carhart-Harris et al., Lancet Psychiatry 2016)¹² and was reorganised in 2019 as the world’s first university-based Centre for Psychedelic Research.¹³ Hopkins followed in 2019 with the Center for Psychedelic and Consciousness Research, endowed by a $17 million philanthropic gift.

In parallel, MAPS executed its multi-decade MDMA-assisted-therapy plan through to Phase 3, with the Phase 3 MAPP1 (Mitchell et al., Nat. Med. 2021)¹⁴ and confirmatory MAPP2 (Mitchell et al., Nat. Med. 2023)¹⁵ studies reporting effect sizes on the Clinician-Administered PTSD Scale that, taken at face value, were among the largest published in PTSD pharmacotherapy. Compass Pathways was founded in 2016, received FDA Breakthrough Therapy designation for COMP360 psilocybin in TRD in October 2018, and conducted what was at the time the largest randomised psilocybin trial (COMP001, n=233; Goodwin et al., NEJM 2022).¹⁶ Usona Institute received Breakthrough Therapy designation for psilocybin in MDD in November 2019.¹⁷

Cultural transmission moved through parallel channels. Michael Pollan’s How to Change Your Mind (Penguin, 2018) sat on the New York Times nonfiction list and is plausibly the single most consequential popular-press event of the decade for U.S. middle-class attitudes; the Netflix adaptation followed in July 2022.¹⁸¹⁹ Coverage in The New Yorker, The Atlantic and Scientific American between 2014 and 2022 normalised the language of “psychedelic therapy” in venues where, fifteen years earlier, it would have been confined to subcultural press.

Decriminalisation moved in lockstep but on a separate track from the FDA pathway. Denver passed Initiated Ordinance 301 in May 2019, making it the first U.S. jurisdiction to deprioritise psilocybin enforcement (50.6% in favour).²⁰ Oakland followed in June 2019 with a unanimous city-council resolution covering entheogenic plants and fungi more broadly; Santa Cruz did the same in January 2020.²¹²² A growing decentralised “Decriminalize Nature” movement extended the pattern to roughly two dozen U.S. cities by 2023. State-level reform proceeded on a different model: Oregon Measure 109 passed in November 2020 by 56% as the first U.S. statute creating a regulated adult-use psilocybin services framework, taking effect 1 January 2023; Colorado Proposition 122 followed in November 2022 with a broader natural-medicine framework covering psilocybin, psilocyn, DMT, ibogaine and mescaline.

1.5 The 2024 correction

The post-2010 trajectory met its first sustained regulatory and reputational pushback in mid-2024. On 4 June 2024, the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) met to consider Lykos Therapeutics’ New Drug Application for midomafetamine (MDMA) capsules with assisted psychotherapy for adult PTSD. The committee voted 2–9 that the available data did not show the treatment to be effective and 1–10 that the benefits did not outweigh the risks — votes that, given the unusually small AdCom dissent on each question, represented an emphatic negative recommendation.²³ Committee members’ concerns clustered around functional unblinding (an estimated 90% of MDMA-arm participants correctly guessed their assignment), expectancy effects, the conflation of pharmacotherapy with a non-manualised psychotherapy of contested theoretical lineage, gaps in adverse-event reporting (notably suicidality), and questions about generalisability of a recruited population reported to include many participants with prior recreational MDMA exposure. (Methodological forensics of these issues are developed in Chapter XII; this chapter restricts itself to the sociopolitical timeline.)

The Institute for Clinical and Economic Review released its Final Evidence Report on 27 June 2024, with panel votes of 14–1 and 15–0 finding the available evidence inadequate to demonstrate net health benefit for MDMA-assisted therapy compared, respectively, to no MDMA-AT and to short-term trauma-focused psychotherapies; the report declined to compute a health-benefit price benchmark in light of design and conduct concerns.²⁴ On 9 August 2024 the FDA issued a Complete Response Letter denying approval and requesting an additional adequately controlled Phase 3 trial.²⁵ Within days Lykos announced an approximately 75% workforce reduction and the departure of senior executives;²⁶ on 10 August 2024 Psychopharmacology retracted three Lykos-affiliated papers (two pooled analyses of the Phase 2 programme and one on antidepressant taper effects), citing protocol violations amounting to unethical conduct at a Canadian study site and undisclosed competing interests.²⁷ (The underlying 2015 incident in British Columbia involving therapists Richard Yensen and Donna Dryer and participant Meaghan Buisson is treated in Chapter XII.)

The substantive content of these events is taken up methodologically in Chapter XII. The point relevant to this chapter is sociopolitical: the AdCom, the ICER report, the CRL, the layoffs and the retractions arrived within a roughly nine-week window, and their cumulative effect was a visible re-pricing of the field. Equity markets in the listed psychedelic sector retraced sharply; venture funding contracted markedly from the 2020–2022 peak; therapist-training organisations curtailed enrolment; and — perhaps most importantly for the academic culture — a long-suppressed register of methodological caution moved from private correspondence to journal pages and the lay press. The episode functioned, in the language of policy studies, as a focusing event: it crystallised concerns that had circulated for years and reset the discursive baseline against which subsequent claims would be judged.

1.6 The 2026 conversation: chastened bifurcation

The year and a half since the CRL has clarified, rather than resolved, the field’s structural tensions. On the industrial side, the most important development has been the apparent dissociation of the field’s prospects from those of Lykos specifically. Compass Pathways’ COMP005 Phase 3 trial of COMP360 psilocybin (25 mg) in treatment-resistant depression met its primary endpoint in June 2025 with a placebo-adjusted MADRS reduction of −3.6 at Week 6 (p<0.001; n=258, 32 U.S. sites), and the confirmatory COMP006 trial (total dosed n=581 across three arms: 25 mg n=296, 10 mg n=142, 1 mg n=143; primary endpoint compares 25 mg vs 1 mg) replicated this in February 2026 at −3.8 MADRS, with durability data reported through Week 26.²⁸²⁹ These effect sizes are statistically robust but clinically modest on a 60-point scale, and the active-placebo problem (1 mg psilocybin in COMP006; microcrystalline cellulose in COMP005) has not been resolved; nevertheless, an NDA submission is planned for Q4 2026. Other late-stage programmes — Cybin’s CYB003 (deuterated psilocybin analogue, Breakthrough Therapy March 2024), MindMed’s MM120 (LSD d-tartrate for GAD, Breakthrough Therapy March 2024 and JAMA publication of the Phase 2b in 2025), Beckley/atai’s BPL-003 (intranasal 5-MeO-DMT benzoate, Breakthrough Therapy October 2025), and GH Research’s GH001 (inhaled 5-MeO-DMT, Phase 2b with a −15.5 placebo-adjusted MADRS at Day 8 published in JAMA Psychiatry) — have continued, with the atai–Beckley merger completing in November 2025 at a Beckley implied valuation of approximately $370–390 million.³⁰

On the grassroots side, the pattern is one of widening jurisdictional fragmentation rather than retreat. Oregon’s Measure 109 programme, despite well-publicised cost and access problems and nine service-centre closures, recorded 1,509 clients in Q1 2025 across 25 of 34 licensed centres, with 377 active facilitators (Chapter XI). Colorado’s Proposition 122 rules were finalised between June and August 2025, with the first natural-medicine healing centres expected to operate from late 2025; the four-substance expansion to DMT, ibogaine and mescaline is scheduled for June 2026. Australia’s TGA Schedule 8 reclassification (effective 1 July 2023) has accumulated approximately 134 patients by September 2025 across 13 authorised prescribers in five states. Czechia passed medical-psilocybin legislation in June 2025 with implementation expected in 2026, Germany’s Federal Institute for Drugs and Medical Devices approved an EU-first compassionate-use programme for psilocybin in TRD in July 2025, and the U.K. MHRA in July 2025 issued a policy waiver removing the domestic controlled-drug licence requirement for approved Schedule I research at universities and hospitals.

The interpretive frame appropriate to the 2026 moment is one of two cultures — to borrow C.P. Snow’s phrase out of context. The industrial/regulatory culture has reverted (productively) to a register of incremental, statistically modest, methodologically defensible claims, and has accepted that single-trial mystical-experience effect sizes were unsustainable as a regulatory standard. The grassroots/state culture has continued to expand on a logic of access, harm-reduction and cognitive liberty that is largely indifferent to FDA-grade endpoints. The two cultures share substances, personnel and rhetoric, but they answer to different epistemic constituencies — and 2024–2026 has made that asymmetry visible in a way it was not in 2018. Whether the divergence stabilises into productive division of labour, or hardens into mutual delegitimisation, is the open question against which the remaining chapters of this review are written.

References

← Overview · Overview · Ch. II →